AndroGel Mental Health and Mood Impact: What the Evidence Actually Shows

What Is AndroGel and Who Is It Prescribed For?

AndroGel is a hydroalcoholic testosterone gel available in 1% (50 mg/5 g packet or pump) and 1.62% (20.25 mg or 40.5 mg per actuation) formulations. The FDA approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011, both for male hypogonadism caused by conditions affecting the testes, pituitary, or hypothalamus. Prescribing information is maintained at the FDA label database. [1]

Hypogonadism affects roughly 2-6% of men overall, rising to 20-30% in men older than 70, according to CDC population data. [2] Low testosterone is associated with depressive symptoms, fatigue, reduced libido, and cognitive complaints, which is precisely why the mental health question receives so much attention clinically.

Diagnosing Low Testosterone Before Starting Therapy

The Endocrine Society's 2018 Clinical Practice Guideline requires two separate morning serum total testosterone measurements below the laboratory reference range (typically below 300 ng/dL) before initiating therapy. [3] Symptoms alone are not sufficient. A man with a PHQ-9 score suggesting mild depression but normal testosterone does not meet the biochemical threshold for AndroGel treatment.

How AndroGel Is Applied

Patients apply the gel to clean, dry, intact skin of the shoulders, upper arms, or abdomen (1.62% only) once daily. Peak serum testosterone is achieved within 2 hours of application; steady-state levels are typically reached by day 14. [1] The gel dries in 3-5 minutes and should not be washed off for at least 2 hours post-application.

The T-Trials: The Largest Randomized Evidence Base

The Testosterone Trials (T-Trials) represent the most rigorous examination of testosterone therapy in older hypogonadal men to date. Published in the New England Journal of Medicine in 2016 (N=790, mean age 72 years, mean baseline total T 232 ng/dL), the T-Trials randomized men to testosterone gel titrated to a mid-normal serum level (500 ng/dL target) or placebo gel for 12 months. [4]

The T-Trials were actually seven coordinated trials run simultaneously, each addressing a different outcome domain: sexual function, physical function, vitality, cognitive function, bone density, cardiovascular effects, and anemia.

Sexual Function and the Mood-Libido Connection

The Sexual Function Trial within T-Trials showed that testosterone improved sexual activity, sexual desire, and erectile function scores significantly compared with placebo (P<0.001 for sexual desire). [4] Because reduced libido is both a symptom of hypogonadism and a driver of mood disturbance, this improvement carries indirect mental health relevance. Men who regained sexual desire reported higher scores on the PDSS (Psychosexual Daily Questionnaire) and parallel improvements in relationship satisfaction domains.

The Vitality Trial: Energy and Fatigue

The Vitality Trial (a sub-trial within T-Trials, N=790) used the FACIT-Fatigue scale as its primary endpoint. Testosterone produced a statistically significant improvement in fatigue scores vs. Placebo (adjusted difference 2.5 points, 95% CI 0.8-4.2, P=0.004), though the absolute change was modest. [4] The Functional Assessment of Chronic Illness Therapy-Fatigue scale has a minimal clinically important difference of approximately 3-4 points, so the mean effect sits just below that threshold. Some individual responders, particularly those with baseline fatigue scores in the lowest tertile, showed larger gains.

The Cognitive Function Trial: A Sobering Result

Testosterone did not improve cognitive function in the T-Trials Cognitive Function Trial. The primary outcome, a composite z-score across memory, executive function, and processing speed, showed no significant difference between testosterone and placebo at 12 months. [4] This null result is important because it contradicts earlier observational data suggesting a protective role for testosterone in dementia risk.

A 2019 re-analysis of T-Trials data published in Annals of Internal Medicine confirmed that testosterone improved bone density and anemia but produced no benefit on the cognitive composite. [5]

Testosterone, Depression, and the PHQ-9 Data

Depression and hypogonadism overlap substantially. A meta-analysis of 27 randomized controlled trials (N=1,890) published in JAMA Psychiatry in 2019 found that testosterone therapy significantly reduced depressive symptom scores compared with placebo (standardized mean difference -0.21, 95% CI -0.32 to -0.10, P<0.001). [6] That effect size is small by Cohen's conventions, roughly equivalent to adding one active antidepressant to another.

Which Patients Show the Greatest Depression Response?

The same 2019 JAMA Psychiatry meta-analysis found that men with a baseline diagnosis of depression, men receiving concomitant antidepressant therapy, and men with HIV-related hypogonadism showed larger effect sizes than the broader hypogonadal population. [6] Men with normal baseline testosterone who received testosterone for non-hypogonadal reasons showed no significant mood benefit, reinforcing the Endocrine Society's insistence on biochemical confirmation before prescribing. [3]

Supra-Physiologic Levels and Mood Risk

Testosterone is not simply "more is better" for mood. Case series and pharmacovigilance data show that supraphysiologic serum levels (above 1,000-1,200 ng/dL) are associated with irritability, aggression, and hypomanic symptoms. [7] The FDA added a label warning for this reason. [1] Dose titration to mid-normal range (400-700 ng/dL) is the standard clinical target.

PHQ-9 Findings in the T-Trials

Within the T-Trials, the PHQ-9 was a secondary outcome. Testosterone gel produced a 1.5-point mean reduction in PHQ-9 score vs. 0.7 points with placebo at 12 months, a difference that did not reach statistical significance after multiple comparison correction. [4] The minimal clinically important difference for PHQ-9 is 5 points, meaning that on average, testosterone therapy did not produce a clinically meaningful antidepressant effect in this older cohort. Individual responders with both low testosterone and a pre-existing depressive disorder may fare differently.

Anxiety, Quality of Life, and Sleep

Anxiety

Evidence for testosterone's effect on anxiety is thinner than the depression literature. A 12-week randomized trial published in Psychoneuroendocrinology (N=184 hypogonadal men, mean baseline T 198 ng/dL) found a statistically significant reduction in Hamilton Anxiety Rating Scale scores with testosterone gel vs. Placebo (mean difference 3.1 points, P=0.03) at week 12. [8] The effect was most pronounced in men with both low testosterone and baseline anxiety scores above 14 (moderate anxiety threshold).

Quality of Life

Several studies using the Short Form-36 (SF-36) show that testosterone therapy improves the vitality subscale and mental component summary score in hypogonadal men. A Cochrane systematic review of testosterone therapy for male hypogonadism (2023, 35 RCTs, N=5,464) reported a small but consistent improvement in SF-36 mental component scores (weighted mean difference 2.1 points, 95% CI 0.8-3.4). [9]

Sleep Architecture

Testosterone therapy has a complex relationship with sleep. Low testosterone is associated with poor sleep quality and reduced slow-wave sleep. However, AndroGel can exacerbate obstructive sleep apnea in predisposed men, which would worsen sleep architecture and indirectly harm mood. [1] The FDA label includes a boxed warning section that specifically calls out sleep apnea as an adverse effect requiring monitoring. Clinicians should screen with the STOP-BANG questionnaire before initiating therapy.

Cognitive Function: Closer Look at the Mechanisms and Evidence

The brain contains androgen receptors in the hippocampus, prefrontal cortex, and amygdala. Animal models consistently show testosterone-dependent neuroprotection and neurogenesis. Despite this mechanistic rationale, translating animal data to human RCT outcomes has proven difficult.

Memory

The T-Trials Cognitive Function Trial used the Modified Rey Auditory Verbal Learning Test (RAVLT) as its primary memory measure. At 12 months, mean scores were virtually identical between testosterone and placebo groups (adjusted difference 0.1 SD, P=0.92). [4] A smaller 6-month RCT in men aged 40-70 with mild cognitive complaints (N=112) published in Neuropsychopharmacology showed a statistically significant improvement in spatial memory with testosterone gel vs. Placebo, but the effect did not hold at 12-month follow-up. [10]

Processing Speed and Executive Function

Processing speed and executive function showed no significant testosterone benefit in the T-Trials. Earlier observational data from the Baltimore Longitudinal Study of Aging suggested an association between higher free testosterone and better performance on Trail Making Test B, but association does not establish causation and the RCT literature has not replicated it. [10]

Alzheimer's Disease Risk

A 2023 review in JAMA Neurology examined longitudinal data from 11 cohort studies and found no consistent association between testosterone replacement therapy and reduced Alzheimer's incidence after controlling for cardiovascular comorbidities. [11] Testosterone therapy is currently not recommended for cognitive preservation outside of clinical trials.

Safety Signals Relevant to Mental Health Monitoring

Cardiovascular Risk and Mood

The TRAVERSE trial (N=5,246 hypogonadal men with elevated cardiovascular risk, median follow-up 33 months), published in the New England Journal of Medicine in 2023, found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) but increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury. [12] Cardiovascular disease is itself a major driver of depression, so monitoring cardiac health is not separable from mental health management in men on AndroGel.

Erythrocytosis and Fatigue Confusion

Hematocrit rises above 54% in approximately 5% of men on AndroGel at standard doses. [1] Erythrocytosis can cause headache, plethora, and fatigue that patients may misinterpret as mood disturbance or worsening depression. Checking a complete blood count at 3 months and 12 months of therapy, per Endocrine Society guidelines, helps distinguish hematologic from psychiatric symptoms. [3]

Polycythemia and Dose Reduction

If hematocrit exceeds 54%, the AndroGel prescribing information recommends discontinuing therapy until hematocrit falls to a safe level, then restarting at a lower dose. [1] Abrupt discontinuation can cause a transient drop in serum testosterone, which may temporarily worsen mood and fatigue, a withdrawal-like effect that patients should be counseled about in advance.

Endocrine Society and AUA Guideline Positions on Mood

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We recommend against starting testosterone therapy in patients with the sole goal of improving mood or depressive symptoms in the absence of biochemically confirmed hypogonadism." [3] This is a strong recommendation based on moderate-quality evidence.

The American Urological Association 2018 Testosterone Deficiency Guideline echoes this position and adds that clinicians should use validated tools, specifically the PHQ-9 and the Hypogonadism Impact of Symptoms questionnaire, to track mood at baseline and at 3, 6, and 12 months after initiation. [13]

A practical clinical framework for mood monitoring on AndroGel therapy involves four steps. First, establish baseline PHQ-9, FACIT-Fatigue, and total testosterone before prescribing. Second, recheck serum testosterone and PHQ-9 at 6-8 weeks to confirm target range and early symptom response. Third, assess at 3 months for the primary mood signal, since most responders show measurable PHQ-9 change by week 12. Fourth, if PHQ-9 has not improved by at least 3 points at 6 months despite testosterone levels in the normal range, refer to psychiatry rather than escalating dose.

Practical Dosing and Titration for Mood Optimization

Starting Dose

The standard starting dose for AndroGel 1.62% is one pump actuation (20.25 mg testosterone) applied to each shoulder daily, for a total of 40.5 mg. [1] The starting dose for AndroGel 1% is one 50 mg packet (5 g gel). Both formulations target serum total testosterone of 400-700 ng/dL at steady state, checked as a morning trough 2-4 hours after application.

Titration Schedule

Dose adjustments are made at 2-week intervals based on morning serum testosterone. For AndroGel 1.62%, the dose can be increased to 81 mg/day (two full-pump applications per shoulder) or decreased to 20.25 mg/day. For AndroGel 1%, the range is 25-100 mg/day. Levels above 1,000 ng/dL should prompt dose reduction given the mood and cardiovascular risk at supraphysiologic concentrations. [1]

Monitoring Timeline for Mood Outcomes

Most mood benefits, when they occur, appear within 3-6 weeks of achieving therapeutic serum testosterone levels. The 2019 JAMA Psychiatry meta-analysis noted that studies with follow-up shorter than 8 weeks frequently showed no significant mood effect, suggesting that short treatment trials may underestimate benefit or harm. [6] A minimum 12-week therapeutic trial at target serum levels is reasonable before concluding non-response.

Transfer Risk and Household Safety

AndroGel poses a real risk of secondary testosterone exposure to female partners and children through skin-to-skin contact. The FDA issued a black box warning in 2009 following reports of virilization in children after indirect gel exposure. [1] Women who become pregnant after unprotected contact with an AndroGel user may expose the fetus. Mental health clinicians should be aware that aggression or behavioral changes in a child living with a male AndroGel user could represent unintended testosterone exposure rather than a primary psychiatric diagnosis.